HAWK Biosystems — Series A (estimated) · €3.5M

HAWK Biosystems, a precision cancer-diagnostics company in the Bizkaia Technology Park and a UMH spin-off, closed a €3.5M round led by Inveready, with the EIC Fund, the Basque Fund (SPRI Group) and other investors. The round takes total funding since founding to about €12.5M. The money goes to pharma partnerships, EU and US expansion, and IVDR CE marking (expected Q2 2027) for its QF-Pro platform.